Sanofi (GCVRZ) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Sanofi stock price
Sanofi latest news:
Regeneron's stock rallies after profit and sales rise above expectations
Shares of Regeneron Pharmaceuticals Inc. rallied 2.6% in premarket trade Wednesday, after the biotechnology company reported third-quarter profit and revenue that rose above expectations. Net income increased to $388.3 million, or $3.32 a share, from $264.8 million, or $2.27 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came to $3.99, beating the FactSet consensus of $3.82. Revenue rose to $1.50 billion from $1.22 billion, above the FactSet consensus of $1.45 billion, as net product sales, Sanofi collaboration revenue and Bayer collaboration revenue all beat expectations. Sales of its lead retinal therapy Eylea rose 12% to $953 million, beating the FactSet consensus of $935 million. The stock has fallen 14% over the past three months through Tuesday, while the iShares Nasdaq Biotechnology ETF has slipped 0.1% and the S&P 500 has gained 4.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UPDATE 1-Sanofi refines expectations on drop in sales at diabetes arm
PARIS, Nov 2 (Reuters) - Sanofi confirmed its 2017
outlook after it posted slightly lower-than-expected
third-quarter results, and gave a more precise range on
expectations of a sales decline at its embattled diabetes
Pfizer sets date for auction of consumer healthcare unit: Reuters
Pfizer Inc. will begin the auction process for its consumer healthcare unit in November, which it hopes will end in a $15 billion sale, Reuters reported late Wednesday, citing sources close to the matter. GlaxoSmithKline PLC. and Reckitt Benckiser are among those companies that have said they would consider bidding for the Pfizer unit. One of the sources told Reuters that initial discussions with Reckitt have already happened. Other possible bidders may include Procter & Gamble , Sanofi SA , Johnson & Johnson and Nestle [s:
ch:nesn], sources said. The companies have been contacted for comment.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Impax Labs shares rise on FDA approval of generic Renvela
Impax Laboratories Inc. shares rose in the extended session Monday after the drug maker said the Food and Drug Administration approved its generic version of Sanofi SA's Renvela. Impax shares advanced 5.7% to $21.50 after hours. The company said sales of the sevelamer carbonate, the generic name for Renvela, are reflected in its earnings outlook of 55 cents to 70 cents a share this year. Analysts surveyed by FactSet expect earnings of 70 cents a share.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
CORRECTED-UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study
Oct 16 (Reuters) - Regeneron Pharmaceuticals Inc
and Sanofi SA said on Monday their drug to treat
inflammation in the esophagus, mainly caused by food allergies,
met the main goal of a mid-stage study.
UPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis treatment
Sanofi and Alnylam Pharmaceuticals Inc. on Wednesday reported positive results in a late-stage trial of a treatment for Hereditary ATTR (hATTR) Amyliodosis patients with polyneuropathy. Alnylam shares jumped 24% after resuming trading following a halt. In a joint statement, the companies said an investigational RNAi therapeutic met its primary and secondary endpoints. The disease is an inherited one that is progressively debilitating and often fatal and is caused by mutations in the TTR gene. TTR protein is produced in the liver and usually acts as a carrier for vitamin A. Mutations can cause proteins to accumulate and damage organs and tissue, including the heart. About 50,000 people worldwide suffer from the disease, which currently has no approved treatment apart from liver transplant. Patients typically have a life expectancy of 2.5 to 15 years after the first symptoms appear. "This is a significant milestone that supports our belief that RNAi therapeutics have the potential to become an innovative new class of medicines for patients with rare genetic diseases," said Elias Zerhouni, M.D., president, global R&D at Sanofi in a statement. Alnylam shares had gained 100.4% in 2017 through Tuesday, while the S&P 500 has gained 12%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UPDATE 2-Regeneron, Sanofi asthma drug data fails to excite investors
PARIS, Sept 11 (Reuters) - Shares of Regeneron Inc
and Sanofi SA slid on Monday after late-stage trial
data for their asthma drug, dupilumab, fell short of investor
BRIEF-Regeneron, Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma
Regeneron Pharmaceuticals Inc(REGN). * Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma. * Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma. * Co, Sanofi announced pivotal phase 3 liberty asthma quest study of met its two primary endpoints.
Sapiens International Corporation N.V.SPNS
Sarepta Therapeutics, Inc.SRPT
SB Financial Group, Inc.SBFG
SB Financial Group, Inc.SBFGP
SBA Communications CorporationSBAC
Schmitt Industries, Inc.SMIT
Schnitzer Steel Industries, Inc.SCHN
SciClone Pharmaceuticals, Inc.SCLN